UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii

Frontiers in microbiology, 2022-09, Vol.13, p.1013934-1013934

2022

Volltextzugriff (PDF)

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii

Frontiers in microbiology, 2022-11, Vol.13, p.1024702-1024702

2022

Volltextzugriff (PDF)

Proposed Strategies for the Integration of Genomics in Primary Care

The American journal of medicine, 2016-07, Vol.129 (7), p.e87-e87

2016

Volltextzugriff (PDF)

Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic

Drug discovery today, 2021-06, Vol.26 (6), p.1337-1339

2021

Volltextzugriff (PDF)

QT Correction: Using an Observed Regression Factor Applicable to a Population Subset

Journal of pharmacy & pharmaceutical sciences, 2016-01, Vol.19 (1), p.25

2016

Volltextzugriff (PDF)

Safety and pharmacology of oseltamivir in clinical use

Drug safety, 2003-01, Vol.26 (11), p.787-801

2003

Volltextzugriff (PDF)

Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better?

Drug discovery today, 2023-08, Vol.28 (8), p.103674-103674, Article 103674

2023

Volltextzugriff (PDF)

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies

Drug metabolism and disposition, 2002-01, Vol.30 (1), p.13-19

2002

Volltextzugriff (PDF)

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective

Drug discovery today, 2020-01, Vol.25 (1), p.1-3

2020

Volltextzugriff (PDF)

Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling

Clinical pharmacokinetics, 2022-10, Vol.61 (10), p.1427-1441

2022

Volltextzugriff (PDF)

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

European journal of clinical pharmacology, 2003-09, Vol.59 (5-6), p.411-415

2003

Volltextzugriff (PDF)

A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases

Therapeutic innovation & regulatory science, 2019-05, p.216847901984566

2019

Volltextzugriff (PDF)

Fixed-dose combinations: a potential means to boost drug development for selected drugs

Drug discovery today, 2018-03, Vol.23 (3), p.457-459

2018

Volltextzugriff (PDF)

A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases

Therapeutic innovation & regulatory science, 2019-05, p.2168479019845667

2019

Volltextzugriff (PDF)

Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules

International journal of pharmaceutics, 2003-05, Vol.257 (1), p.297-299

2003

Volltextzugriff (PDF)

A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

Journal of clinical pharmacology, 2016-03, Vol.56 (3), p.257-259

2016

Volltextzugriff (PDF)

Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development

Expert review of clinical pharmacology, 2016-06, Vol.9 (6), p.747-749

2016

Volltextzugriff (PDF)

A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats

Journal of pharmaceutical sciences, 2010-01, Vol.99 (1), p.227-233

2010

Volltextzugriff (PDF)

A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases

Therapeutic innovation & regulatory science, 2020-03, Vol.54 (2), p.444-446

2020

Volltextzugriff (PDF)

Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin

Antimicrobial Agents and Chemotherapy, 2002-06, Vol.46 (6), p.1993-1995

2002

Volltextzugriff (PDF)

Does Erythromycin Have Anti-Inflammatory Effects Independent of Its Antimicrobial Action?

Journal of clinical pharmacology, 2012-04, Vol.52 (4), p.613-614

2012

Volltextzugriff (PDF)

In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver

Xenobiotica, 2014-02, Vol.44 (2), p.154-163

2014

Volltextzugriff (PDF)

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

Paediatric drugs, 2001, Vol.3 (3), p.229-236

2001

Volltextzugriff (PDF)

There is no better time than the present: nanotechnology as a disruptive innovation for drug development

Drug discovery today, 2015-06, Vol.20 (6), p.645-647

2015

Volltextzugriff (PDF)

Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults

Antimicrobial Agents and Chemotherapy, 2000-10, Vol.44 (10), p.2672-2678

2000

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(83)
Mit Volltextzugriff
(67)

Publikationsform

Sprache

Englisch
(86)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(71)
Life Sciences & Biomedicine
(69)
Humans
(44)
Pharmacology & Pharmacy
(29)
Male
(23)
Biological And Medical Sciences
(21)
Female
(19)
Adult
(17)
Medical Sciences
(17)
Animals
(16)
Middle Aged
(14)
Pharmacology. Drug Treatments
(11)
Acetamides - Pharmacokinetics
(7)
Aged
(7)
Antibiotics. Antiinfectious Agents. Antiparasitic Agents
(7)
Antiviral Agents
(7)
Antiviral Agents - Pharmacokinetics
(7)
Drug Interactions
(7)
Oseltamivir
(7)
Influenza, Human - Drug Therapy
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metabolomic profiling of polymyxin-B in combination with meropenem and sulbactam against multi-drug resistant Acinetobacter baumannii

The combination effect of meropenem/sulbactam/polymyxin-B on the pharmacodynamic parameters for mutant selection windows against carbapenem-resistant Acinetobacter baumannii

Proposed Strategies for the Integration of Genomics in Primary Care

Revamping the ever-changing landscape of drug development processes in the midst of COVID-19 pandemic

QT Correction: Using an Observed Regression Factor Applicable to a Population Subset

Safety and pharmacology of oseltamivir in clinical use

Evaluating the status of antibiotic approvals and readiness to combat antimicrobial resistance: What else can we do better?

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies

Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective

Prediction of Tissue Exposures of Meropenem, Colistin, and Sulbactam in Pediatrics Using Physiologically Based Pharmacokinetic Modeling

Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years

A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases

Fixed-dose combinations: a potential means to boost drug development for selected drugs

A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases

Pharmacokinetics and delivery of the anti-influenza prodrug oseltamivir to the small intestine and colon using site-specific delivery capsules

A personal perspective of orphan drug development for rare diseases: A golden opportunity or an unsustainable future?

Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development

A feasibility study of differential delivery of levodopa ester and benserazide using site-specific intestinal loops in rats

A Time of Optimism: Targeted Immunotherapeutics as the Long-Awaited Armamentaria Against the Scourge of Human Diseases

Lack of Pharmacokinetic Interaction between the Oral Anti-Influenza Prodrug Oseltamivir and Aspirin

Does Erythromycin Have Anti-Inflammatory Effects Independent of Its Antimicrobial Action?

In vitro and in vivo metabolism of a novel chymase inhibitor, SUN13834, and the predictability of human metabolism using mice with humanized liver

Pharmacokinetics and dosage recommendations for an oseltamivir oral suspension for the treatment of influenza in children

There is no better time than the present: nanotechnology as a disruptive innovation for drug development

Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults

Suchergebnisse filtern